Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lead to therapy resistance and escape from immune control before establishing acquired resistance genetically. We used genome-wide transcriptomics and single-cell phenotyping to explore the response kinetics to BRAF inhibition for a panel of patient-derived BRAF^(V600)-mutant melanoma cell lines. A subset of plastic cell lines, which followed a trajectory covering multiple known cell state transitions, provided models for more detailed biophysical investigations. Markov modeling revealed that the cell state transitions were reversible and mediated by both Lamarckian induction and nongenetic Darwinian selection of drug-tolerant states. Single-cel...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lea...
Cancers commonly develop resistance against chemotherapeutics or targeted therapies through either g...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
We resolved a mechanism connecting tumor epigenetic plasticity with non-genetic adaptive resistance ...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
Drug resistance strongly impairs the efficacy of virtually every kind of anticancer therapy. This ph...
Abstract Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of th...
Cancer cells within tumors display a high degree of phenotypic variability. This variability is thou...
The treatment of melanoma by targeted inhibition of the mutated kinase BRAF with small molecules onl...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lea...
Cancers commonly develop resistance against chemotherapeutics or targeted therapies through either g...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plastic...
We resolved a mechanism connecting tumor epigenetic plasticity with non-genetic adaptive resistance ...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
Drug resistance strongly impairs the efficacy of virtually every kind of anticancer therapy. This ph...
Abstract Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of th...
Cancer cells within tumors display a high degree of phenotypic variability. This variability is thou...
The treatment of melanoma by targeted inhibition of the mutated kinase BRAF with small molecules onl...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...